- Dummy
-
Dummy dummy dummy
dummy dummy.
- At a Glance
-
Your health is
our specialty.
- Sustainability
-
Our commitment to
grow and improve
- History
-
From humble beginnings
to an industry leader
- Our Business
-
What we do to
enrich people’s lives
- Our Products
-
Our offerings for
all aspects of your life
About Taisho Pharmaceutical Group
Latest News
News
-
HoldingsJanuary 16, 2024
Investors - Notice Regarding the Results of the Tender Offer by Otemon Co., Ltd. for the Company Shares Etc. and Change of the Parent Company and the Largest Shareholder Among the Major Shareholders
-
Group CompanyJanuary 16, 2024
Products - Launch of Nanozora® 30mg Autoinjector for S.C. Injection
-
Group CompanyDecember 1, 2023
Products - Notification of the Approval of Home Self-injection Guidance and Management Fees and the Derestriction of the Dosing Period for NanozoraⓇ
-
Group CompanyAugust 1, 2023
R&D - Notification of Approval to Manufacture and Market Nanozora® 30mg Autoinjectors for S.C. Injection in Japan
-
Group CompanyJune 21, 2023
Corporate - Taisho Pharmaceutical and Biolinq Announce Strategic Collaboration and Exclusive License Agreement in Japan